Full Report - Research for Development - Department for ...

Author
(year)
(IV)/(EV)
Aaby
(2005)
(++)/(+)
Amin
(1992)
(-)/(-)
Benn
(2008a)
(+)/(++)
Benn
(2008b)
(++)/(++)
Target
Population
Infants in
general
Infants in
general
Neonates in
general
Neonates in
general
Brief intervention description Targeted
outcome(s)
National immunisation days for oral polio
vaccine (OPV) administered alone.
Infant
mortality
Expanded Programme on Immunization (EPI). Infant
mortality
Infant vitamin A supplementation (VAS).
Normal birthweight infants were
administered 50,000 IU VAS or placebo with
BCG.
Infant VAS. Normal birthweight infants were
administered 50,000 IU VAS or placebo with
BCG.
Infant
mortality
Infant
mortality
Findings summary
Appendix 4.2
OPV was associated with a beneficial effect
for children under 6 months of age at the
time of the campaign, but the difference
was not significant for all children under 5
years of age. The effect of OPV among
children less than 6 months of age could be
due to selection bias but might also
represent a non-specific beneficial immune
stimulation.
There was a decline in infant mortality in
1988-89 compared to earlier periods. The
decline seemed to have been the result of
immunisation coverage, which had
considerably increased by 1989-90,
reaching above 70% of children under age
5.
VAS administered with BCG vaccine at birth
had no significant effect on infant mortality
in this African setting.
VAS administered with BCG vaccine at birth
had no significant effect on infant mortality
in this African setting.
What are the effects of different models of delivery for improving maternal and infant health outcomes for poor people in urban areas in low income
and lower middle income countries?
211